share_log

公告精选 | 中广核新能源年内光伏发电同比增超18%;越秀地产首季合同销售同比跌逾五成

Selected announcements | CGN New Energy's photovoltaic power generation increased by more than 18% year on year; contract sales of Yuexiu Real Estate in the first quarter fell by more than 50% year on year

cls.cn ·  Apr 11 07:38

① Yuexiu Real Estate's contract sales in the first quarter fell by more than 50% year on year. How did other real estate companies monetize?

② CGN New Energy's photovoltaic power generation increased by 18% during the year. What are the highlights of other businesses?

The important announcements for Hong Kong stocks yesterday are as follows:

Operational data

$YUEXIU PROPERTY (00123.HK)$: In the first 3 months, cumulative contract sales amounted to RMB 21.702 billion, a year-on-year decrease of about 50.5%.

$LONGFOR GROUP (00960.HK)$: In the first 3 months, cumulative contract sales amounted to 23.48 billion yuan, a year-on-year decrease of 53.7%.

$YUZHOU GROUP (01628.HK)$: In the first 3 months, the total contract sales were 2,208 billion yuan, with an average price of 15,744 yuan.

$YUE YUEN IND (00551.HK)$: The consolidated cumulative net operating income for the first quarter was US$2.03 billion, a year-on-year decrease of 4.94%.

$POU SHENG INT'L (03813.HK)$: The consolidated cumulative net operating revenue for the first quarter was 5.4 billion yuan, down 7.5% year on year.

$CGN NEW ENERGY (01811.HK)$: A total of 4956.7 gigawatt-hours of power generation was completed in the first 3 months, an increase of 0.3% over 2023. Among them, China's wind power projects increased by 4.4%, China's solar energy projects increased by 18.1%, China's cogeneration and gas projects increased by 8.2%, China's hydropower projects increased by 3.9%, and South Korea's projects decreased by 10.4%.

$WASION HOLDINGS (03393.HK)$: Weisheng Group, a subsidiary of the company, won contracts for about 899,000 smart meters from the State Grid, with a contract value of approximately RMB 306 million. In addition, Weisheng Information Technology Co., Ltd. also won contracts for approximately 56,000 data collection terminals and concentrators, with a contract value of approximately RMB 106 million.

Pharmaceutical Innovation

$SINO BIOPHARM (01177.HK)$: Three innovative drugs announced six research results at AACR

$SH PHARMA (02607.HK)$: Rabeprazole sodium enteric tablets passed generic drug consistency evaluation

$SHANDONG XINHUA (00719.HK)$: Cefaclor capsules passed generic drug consistency evaluation

Buyback News

$PAGODA GP (02411.HK)$: A number of controlling shareholders who collectively control about 693 million shares of the company made voluntary sales bans until April 10, 2025. The shares involved are equivalent to approximately 43.64% of the company's total registered share capital.

$TENCENT (00700.HK)$: A repurchase of 3.2 million shares was spent at HK$1,001 billion, with a repurchase price of HK$307-315.2 per share.

$MEITUAN-W (03690.HK)$: Approximately HK$400 million was spent to repurchase 3.8817 million shares at a repurchase price of HK$99.7-104.7 per share.

$HSBC HOLDINGS (00005.HK)$: HK$300 million was spent to repurchase 4.7 million shares at a repurchase price of HK$63.7-64.1 per share.

$TUHU-W (09690.HK)$: Spend HK$357.215 million to repurchase 2 million shares at a repurchase price of HK$17.6-17.98 per share.

$CK ASSET (01113.HK)$: 752,500 shares were repurchased at HK$24.528,600 at a repurchase price of HK$32.45 to HK$32.65 per share.

$SWIRE PACIFIC A (00019.HK)$: A repurchase of 193,000 shares was spent at HK$12.258,300, at a repurchase price of HK$62.9-HK$64.25 per share.

edit/new

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment